Stock Earnings

Question 1

What are Denali Therapeutics Inc's key financial statements?

Accepted Answer

According to the latest financial statement (Form-10K), Denali Therapeutics Inc has a total asset of $1,374, Net loss of $-422

Question 2

What are the key financial ratios for DNLI?

Accepted Answer

Denali Therapeutics Inc's Current ratio is 9.54, has a Net margin is 0, sales per share of $0.

Question 3

How is Denali Therapeutics Inc's revenue broken down by segment or geography?

Accepted Answer

Currently Denali Therapeutics Inc data is not available.

Question 4

Is Denali Therapeutics Inc profitable?

Accepted Answer

no, according to the latest financial statements, Denali Therapeutics Inc has a net loss of $-422

Question 5

Does Denali Therapeutics Inc have any liabilities?

Accepted Answer

yes, Denali Therapeutics Inc has liability of 144

Question 6

How many outstanding shares for Denali Therapeutics Inc?

Accepted Answer

Denali Therapeutics Inc has a total outstanding shares of 144.22

Breakdown	TTM	12/31/2024	12/31/2023	12/31/2022	12/31/2021	12/31/2020
Revenue	--	0	330	108	48	335
Revenue Growth (YoY)	--	-100%	206%	125%	-86%	1,188%
Cost of Revenue	--	--	--	--	--	--
Gross Profit	--	--	--	--	--	--
Selling, General & Admin	--	105	103	90	79	60
Research & Development	--	396	423	358	265	212
Operating Expenses	--	501	527	449	344	272
Other Non Operating Income (Expenses)	--	--	--	--	--	--
Pretax Income	--	-422	-145	-326	-291	72
Income Tax Expense	--	0	0	0	0	0
Net Income	--	-422	-145	-326	-290	71
Net Income Growth	--	191%	-56%	12%	-508%	-136%
Shares Outstanding (Diluted)	--	164.47	137.37	125.5	121.5	112.7
Shares Change (YoY)	--	20%	9%	3%	8%	18%
EPS (Diluted)	--	-2.57	-1.05	-2.6	-2.39	0.63
EPS Growth	--	143%	-59%	9%	-479%	-130%
Free Cash Flow	-411	-363	-370	-262	-219	413
Free Cash Flow Per Share	--	-2.2	-2.69	-2.08	-1.8	3.66
Gross Margin	--	--	--	--	--	--
Operating Margin	--	0%	-59.39%	-314.81%	-614.58%	18.5%
Profit Margin	--	0%	-43.93%	-301.85%	-604.16%	21.19%
Free Cash Flow Margin	--	0%	-112.12%	-242.59%	-456.25%	123.28%
EBITDA	--	-493	-180	-330	-287	70
EBITDA Margin	--	0%	-54.54%	-305.55%	-597.91%	20.89%
D&A For EBITDA	13	8	16	10	8	8
EBIT	--	-501	-196	-340	-295	62
EBIT Margin	--	0%	-59.39%	-314.81%	-614.58%	18.5%
Effective Tax Rate	--	0%	0%	0%	0%	0%

Denali Therapeutics Inc (DNLI) Price